Clinical trial
A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone…
NCT00268853 · CTI BioPharma, Industry · Completed
Key facts
| NCT number | NCT00268853 |
|---|---|
| Title | A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin |
| Official title | Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone Plus Rituximab (CPOP-R) in Patients With Diffuse Large-B-cell Lymphoma: A Phase II, Randomized, Multicenter, Comparative Trial |
| Acronym | RAPID |
| Lead sponsor | CTI BioPharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diffuse Large-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | CPOP-R, CHOP-R |
| Enrollment | 124 |
| Start date | Nov 1, 2005 |
| Primary completion | May 1, 2012 |
| Completion | May 1, 2012 |
| First posted | Dec 23, 2005 |
| Last update posted | May 30, 2024 |
| Countries | Canada, France, Germany, Italy, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: